EYEGENE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,110 KRW | -.--% |
|
-4.01% | -27.08% |
| Sales 2022 | 5.29B 3.82M 5.26M | Sales 2023 | 3.13B 2.26M 3.11M | Capitalization | 91.61B 66.14M 91.06M |
|---|---|---|---|---|---|
| Net income 2022 | -25.95B -18.74M -25.8M | Net income 2023 | -21.11B -15.24M -20.98M | EV / Sales 2022 | 8.31 x |
| Net cash position 2022 | 64.06B 46.25M 63.67M | Net cash position 2023 | 52.16B 37.66M 51.85M | EV / Sales 2023 | 12.6 x |
| P/E ratio 2022 |
-4.16
x | P/E ratio 2023 |
-4.37
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.98% |
More Fundamentals
* Assessed data
More news
| 1 week | -4.01% | ||
| Current month | -8.26% | ||
| 1 month | -8.26% | ||
| 3 months | +1.63% | ||
| Current year | -27.08% |
1 week
3 035.00
3 255.00
1 month
3 035.003 475.00
Current year
2 935.004 415.00
1 year
2 800.004 895.00
3 years
2 800.0060 200.00
5 years
2 800.0060 200.00
10 years
2 800.0060 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Il Yoo
CEO | Chief Executive Officer | 60 | 00-06-22 |
Myeong-Jae Rhee
DFI | Director of Finance/CFO | 54 | 12-04-30 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 56 | 00-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Doo Choi
AUD | Comptroller/Controller/Auditor | 55 | 12-02-29 |
Won-Il Yoo
CEO | Chief Executive Officer | 60 | 00-06-22 |
Yang-Je Cho
CTO | Chief Tech/Sci/R&D Officer | 56 | 00-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 3,110 | -.--% | 36,129 |
| 24-04-29 | 3,110 | +2.30% | 42,812 |
| 24-04-26 | 3,040 | -1.30% | 52,514 |
| 24-04-25 | 3,080 | -1.75% | 76,657 |
| 24-04-24 | 3,135 | -2.03% | 29,667 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
EyeGene, Inc. is a Korea-based company mainly engaged in the development of therapeutics, diagnostics, and technologies for eye-related diseases. The Companyâs products consist of EG-Mirotin, which is a therapeutics of ocular angiogenesis of the diagnostic of early-stage of diabetic retinopathy (DR) and retinopathy of prematurity (ROP); EG-Decorin, a topical ointment for pressure ulcer and diabetic foot ulcer; EG-HPV, a human papillomavirus vaccine; EGS, a scarless wound repair agent, and EG-Vac, a novel vaccine adjuvant for various vaccine preparations.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.08% | 60.74M | |
| +32.96% | 704B | |
| +28.59% | 577B | |
| -3.83% | 348B | |
| +18.32% | 327B | |
| +5.44% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.93% | 147B |
- Stock Market
- Equities
- A185490 Stock
